15353-j-veluchamy

6 General discussion and Future Prospects | 157 11. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105 (8):3051-7. Epub 2005/01/06. doi: 10.1182/blood-2004-07-2974. PubMed PMID: 15632206. 12. Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, MottaMR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood (2011) 118 (12):3273-9. Epub 2011/07/28. doi: 10.1182/ blood-2011-01-329508. PubMed PMID: 21791425. 13. Miller JS. Therapeutic applications: natural killer cells in the clinic. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program (2013) 2013 :247-53. Epub 2013/12/10. doi: 10.1182/asheducation-2013.1.247. PubMed PMID: 24319187. 14. Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Molecular therapy : the journal of the American Society of Gene Therapy (2014) 22 (7):1388-95. Epub 2014/04/02. doi: 10.1038/mt.2014.50. PubMed PMID: 24686272; PubMed Central PMCID: PMCPMC4089007. 15. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends in pharmacological sciences (2012) 33 (1):35-41. Epub 2011/10/29. doi: 10.1016/j. tips.2011.09.004. PubMed PMID: 22032984; PubMed Central PMCID: PMCPMC3327885. 16. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood (2014) 124 (7):1081-8. Epub 2014/07/10. doi: 10.1182/blood-2014-02-556837. PubMed PMID: 25006133. 17. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane- bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 7 (1):e30264. Epub 2012/01/27. doi: 10.1371/journal.pone.0030264. PubMed PMID: 22279576; PubMed Central PMCID: PMCPMC3261192. 18. Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh M, et al. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. Cytotherapy (2016) 18 (5):653-63. Epub 2016/04/10. doi: 10.1016/j.jcyt.2016.02.006. PubMed PMID: 27059202. 19. Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, et al. Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor α/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma. Cancer research (2013) 73 (10):3075-86. doi: 10.1158/0008- 5472.CAN-12-2357. PubMed PMID: PMC3914673. 20. Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, et al. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models. Cancer immunology research (2016) 4 (1):49-60. Epub 2015/10/30. doi: 10.1158/2326-6066.cir-15-0093-t. PubMed PMID: 26511282; PubMed Central PMCID: PMCPMC4703482.